Debbie Etchison News Today

SCYNEXIS announced an exclusive license agreement with GSK plc (LSE/NYSE: GSK) for the global rights to develop and commercialize BREXAFEMME® (ibrexafungerp tablets). SCYNEXIS will receive an upfront payment

Brexafemme complements GSK’s industry-leading infectious disease portfolio with an FDA approved treatment for vulvovaginal candidiasisSCYNEXIS will receive an upfront payment of $90 million with... | March 30, 2023

SCYNEXIS, Inc. (NASDAQ:NASDAQ:SCYX) Q3 2022 Results Conference Call November 9, 2022 08:30 AM ET Company Participants Debbie Etchison - Communications & IR Dr.

Approximately 83% of FURI patients with refractory Candida infections had positive clinical outcomes, defined as complete/partial response or no disease progression . Data from the ongoing Phase... | September 8, 2022

15.08.2022 - BREXAFEMME (ibrexafungerp tablets) prescriptions in Q2 2022 increased 29 percent over Q1 2022, generating net revenues of $1.3 million in Q2 2022, compared to $0.7 million in Q1. SCYNEXIS filed a supplemental New Drug Application (sNDA) to expand ...

Share this article Share this article JERSEY CITY, N.J., May 12, 2021 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced it will present findings from a new analysis of claims data from a cohort of patients who received RADICAVA ® (edaravone) for the treatment of amyotrophic lateral sclerosis (ALS). The analysis will be presented during the 2021 European Network to Cure ALS (ENCALS) Meeting, being held virtually May 12-14. "Initial insights shared with the scientif...

Share this article Share this article JERSEY CITY, N.J., April 20, 2021 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of an analysis of the timing of disease progression milestones among commercially insured amyotrophic lateral sclerosis (ALS) patients treated with intravenous (IV) RADICAVA ® (edaravone). The findings are being presented during the 2021 Virtual American Academy of Neurology (AAN) Annual Meeting, held April 17-22. "We are please...

Mitsubishi Tanabe Pharma America Presents Data on Impact of ALS Symptoms on Patients Ability to Independently Conduct Daily Activities Analysis Shared at 2021 Muscular Dystrophy Association Annual Clinical & Scientific Conference News provided by Share this article Share this article JERSEY CITY, N.J., March 17, 2021 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced findings from a new analysis evaluating the impact of symptom progression on the ability of people wi...

Press release content from PR Newswire. The AP news staff was not involved in its creation. Mitsubishi Tanabe Pharma America Celebrates Five Years of Dedication to the ALS Community in the U.S. February 8, 2021 GMT MTPA Logo (PRNewsfoto/Mitsubishi Tanabe Pharma Americ) JERSEY CITY, N.J., Feb. 8, 2021 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today celebrated its five-year anniversary of being established in the United States in 2016. MTPA has followed an unwavering patient-f...

Share this article Share this article JERSEY CITY, N.J., Jan. 14, 2021 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced upgrades to its out-of-pocket assistance program that aim to provide enhanced support for eligible patients with amyotrophic lateral sclerosis (ALS) treated with RADICAVA ® (edaravone) through more efficient communication and exchange of information, including a new "hybrid" card that can be used to help access appropriate pharmacy and medical co...